Alpha Tau Medical (NASDAQ:DRTS) CFO Raphi Levy Sells 20,000 Shares

Alpha Tau Medical Ltd. (NASDAQ:DRTS) CFO Raphi Levy sold 20,000 shares of the business’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $11.00, for a total value of $220,000.00. Following the sale, the chief financial officer directly owned 110,180 shares of the company’s stock, valued at approximately $1,211,980. This trade represents a 15.36% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Raphi Levy also recently made the following trade(s):

• On Tuesday, June 23rd, Raphi Levy sold 17,500 shares of Alpha Tau Medical stock. The stock was sold at an average price of $9.55, for a total value of $167,125.00.
• On Wednesday, June 3rd, Raphi Levy sold 32,500 shares of Alpha Tau Medical stock. The shares were sold at an average price of $10.83, for a total transaction of $351,975.00.

Alpha Tau Medical Stock Performance

Shares of DRTS stock opened at $11.17 on Friday. The company has a current ratio of 7.79, a quick ratio of 7.79 and a debt-to-equity ratio of 0.09. The company has a market cap of $1.01 billion, a PE ratio of -16.67 and a beta of 1.19. The company’s fifty day simple moving average is $9.33 and its 200-day simple moving average is $7.59. Alpha Tau Medical Ltd. has a 52 week low of $2.87 and a 52 week high of $11.62.

Alpha Tau Medical (NASDAQ:DRTS) last announced its quarterly earnings results on Monday, May 18th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.13). As a group, equities research analysts anticipate that Alpha Tau Medical Ltd. will post -0.67 EPS for the current year.

Analyst Ratings Changes

A number of analysts have recently issued reports on the company. Piper Sandler lifted their target price on Alpha Tau Medical from $5.00 to $8.00 and gave the stock a “neutral” rating in a research report on Tuesday, May 19th. LADENBURG THALM/SH SH raised their price objective on Alpha Tau Medical from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Tuesday, May 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Alpha Tau Medical in a report on Monday, April 20th. Barclays upped their target price on Alpha Tau Medical from $15.00 to $17.00 and gave the company an “overweight” rating in a research report on Thursday, June 4th. Finally, Citigroup raised their price target on shares of Alpha Tau Medical from $7.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, March 11th. Four research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $12.60.

Hedge Funds Weigh In On Alpha Tau Medical

Hedge funds have recently added to or reduced their stakes in the business. Envestnet Asset Management Inc. bought a new position in shares of Alpha Tau Medical in the 3rd quarter worth about $62,000. Bank of America Corp DE raised its stake in Alpha Tau Medical by 2,779.1% during the third quarter. Bank of America Corp DE now owns 22,457 shares of the company’s stock worth $101,000 after acquiring an additional 21,677 shares during the period. Millennium Management LLC bought a new position in Alpha Tau Medical in the third quarter worth about $170,000. Mariner LLC lifted its holdings in Alpha Tau Medical by 185.8% in the third quarter. Mariner LLC now owns 123,250 shares of the company’s stock worth $556,000 after acquiring an additional 80,129 shares during the last quarter. Finally, Apella Capital LLC acquired a new position in Alpha Tau Medical in the fourth quarter valued at approximately $1,892,000. Institutional investors and hedge funds own 2.65% of the company’s stock.

About Alpha Tau Medical

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.